Intravenous chemotherapy for ovarian cancer - The state of the art?

International Journal of Gynecological Cancer

Volumn 10, Issue SUPPL. 1, 2000, Pages 19-25

  Kaye, S B ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Current standards; Intravenous chemotherapy; Ovarian cancer

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033994398     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.99506.x     Document Type: Article

References (33)

1. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses from 37 individual trials. Br J Cancer 1998; 78: 1479-87.
2. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
3. Stuart G, Bertelsen K, Mangioni C et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTCGCCG, NO-COVA, NCIC CTG and Scottish Intergroup trial. Proc Am Soc Clin Oncol 1998; 17: 361a (Abstract).
4. A'Hern R, Gore M. Impact of doxorubicin on survival in ovarian cancer. J Clin Oncol 1995; 13: 726-32.
5. du Bois A, Lueck H, Meier W et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer update of AGO trial. Proc Am Soc Clin Oncol 1999; 18: 356a (Abstract).
6. Neijt JP, Engelholm SA, Tuxen M et al. Paclitaxel-cisplatin vs paclitaxel-carboplatin in previously untreated ovarian cancer. Ann Oncol 1998; 9 (Suppl. 4): 65 (Abstract).
7. Ozols R, Bundy B, Fowler J et al. Randomized Phase III study of cisplatin-paclitaxel in optimal stage in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1999; 18: 356a (Abstract).
8. Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer, 1998 consensus statements. Ann Oncol 1999; 10 (Suppl. 1): S87-92.
9. Bertelsen K, Jakobsen A, Stroyer J et al. A prospective randomised comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced ovarian cancer. Gynaec Oncol 1992; 47: 7-13.
10. Hansen SW, Anderson H, Boman K et al. Gemcitabine, carboplatin and paclitaxel as first-line treatment of ovarian cancer. Proc Am Soc Clin Oncol 1999; 18: 357a (Abstract).
11. Rowinsky EK, Grochow L, Hendricks C et al. Phase I and pharmacologic study of topotecan. J Clin Oncol 1992; 10: 647-56.
12. Rose PG, Blessing JA, Mayer A, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1998; 16: 405-10.
13. Muggia FM, Hainsworth JD, Jeffers S. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-93.
14. Raymond E, Chang SG, Taamma A et al. Oxaliplatin a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-72.
15. Fink D, Aebi S, Howell S. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1-6.
16. Bissery MC, Nohynek G, Lavelle F et al. Docetaxel: review of preclinical and clinical experience. Anticancer Drugs 1995; 6: 339-68.
17. Chan S, Friedrichs K, Noel D et al. A randomized phase III study of Taxotere (T) versus doxorubicin (D) inpatients with metastatic breast cancer who have failed an alkylating containing regimen: preliminary results. Proc Am Soc Clin Oncol 1997; 16: 540 (Abstract).
18. Paridaens R, Bruning P, Klijn J et al. An EORTC crossover trial comparing single-agent Taxol (T) and doxorubicin (D) as first- and second-line chemotherapy (CT) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1997; 16: 539 (Abstract).
19. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere®) in advanced ovarian cancer - an updated overview. Eur J Cancer 1997; 33: 2167-70.
20. Vasey PA, Eggleton SPH, Birt A et al. Docetaxel-cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol 1999 in press.
21. Vasey P, Atkinson R, Coleman R et al. Preliminary report of a dose-finding study of a docetaxel carboplatin combination in untreated advanced epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 1998; 17: 349a (Abstract).
22. Bonaddona G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regime in breast cancer with more that 3 positive nodes. JAMA 1995; 273: 542-7.
23. Henderson IC, Berry D, Demetri G et al. Improved disease free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1998; 17: 101a (Abstract).
24. Wahl A, Donaldson K, Fairchild C et al. Loss of normal p53 function confers sensitization to Taxol. Nature Med 1996; 2: 72-8.
25. Brown R. Cellular responses to DNA damage and cisplatin resistance. In: Sharp F, Blackett T, Leake R, Berek J, eds. Ovarian Cancer 4. London: Chapman & Hall, 1996: 205-13.
26. Muggia FM, Braly PS, Brady MF et al. Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132. Proc Am Soc Clin Oncol 1997; 16: 352a (Abstract).
27. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996; 50: 1536-40.
28. The ICOn Collaborators. ICON-2 randomized trial of single agent carboplatin against 3 drug combination of CAP in women with ovarian cancer. Lancet 1998; 352: 1571-76.
29. Harper P. On behalf of ICON-3 investigators. Randomized comparison of paclitaxel and carboplatin versus single agent carboplatin or GAP. 2075 patients randomized in ICON-3. Proc Am Soc Clin Onc 1999; 18: 356a (Abstract).
30. Rustin G, Nelstrop A, Lambert H. Defining progression of ovarian cancer during follow-up according to CA125. Ann Oncol 1996; 7: 361-4.
31. Leon SA, Shapiro B, Sklarott DM, Yaros MJ. Free DNA in the serum of cancer patients and the effects of therapy. Cancer Res 1997; 37: 648-50.
32. Brown R, Hirst G, Gallacher WM et al. hMLH1 expression and cellular responses of ovarian tumour cells to cytotoxic agents. Oncogene 1997; 15: 45-52.
33. Strathdee G, Mackean M, Illand M, Brown R. The role of methylation of the hMLH1 promoter in loss of hMLH expression and drug resistance in ovarian cancer. Oncogene 1999; 18: 2335-41.